Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.45 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.45 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.45 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.45 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.45 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.45 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.45 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.45 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39955 | 0.98 | TSHR (0.46) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Methyl Alcohol SCHEMBL28031919 | 0.96 | TSHR (0.45) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL3328736 | 0.94 | TSHR (0.43) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Bicarbonate SCHEMBL8301671 | 0.94 | TSHR (0.48) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Acetic Acid SCHEMBL25244912 | 0.92 | TSHR (0.47) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Piperidine SCHEMBL1949563 | 0.91 | HRH3 (0.41) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Acetaldehyde SCHEMBL21114617 | 0.91 | HRH3 (0.41) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL12964597 | 0.91 | SLC6A1 (0.44) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL15904240 | 0.90 | HRH3 (0.40) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL31172943 | 0.90 | HRH3 (0.40) | TSHRGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322143-B | Preparation method of 4-tert-butyl piperidine formate hydrochloride | 安徽德诺医药股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-115322143-A | Preparation method of 4-piperidine formic acid tert-butyl ester hydrochloride | 安徽德诺医药股份有限公司 | 2022-11-11 | — | — | CN | claimed |
| EP-4692057-A1 | NOVEL B0AT1 INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-3833715-B1 | SILICON-SUBSTITUTED RHODAMINE DYES AND DYE CONJUGATES | LIFE TECHNOLOGIES CORP (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673214-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | SOPONPONG JAKAPUN (TH) | 2025-11-27 | — | — | US | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | C4 THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008085117-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008085119-A1 | NEW PYRIDINE ANALOGUES VIII 518 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | GABRP 1027/4885GABRD 407/4885GABRA1 480/4885 |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | GABRP 632/4885GABRD 843/4885GABRA1 367/4885 |
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | GABRP 1848/4885GABRD 2649/4885GABRA1 2140/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | GABRP 451/4885GABRD 629/4885GABRA1 1443/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | GABRP 1021/4885GABRD 2810/4885GABRA1 1412/4885 |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | P2RY12, P2RY11, P2RY1 | GABRP 1478/4885GABRD 2106/4885GABRA1 1854/4885 |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | PDCD1, CD274, PDCD1LG2 | GABRP 643/4885GABRD 2702/4885GABRA1 1636/4885 |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | P2RY12, P2RY13, P2RY11 | GABRP 483/4885GABRD 1287/4885GABRA1 739/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | GABRP 1027/4885GABRD 407/4885GABRA1 480/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | GABRP 874/4885GABRD 3295/4885GABRA1 1427/4885 |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | CRBN, STUB1, CUL1 | GABRP 1027/4885GABRD 407/4885GABRA1 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.